Highlights
About
Neurocognitive and Neurodegenerative Therapies
Coronis Neurosciences is a specialty pharmaceutical company focused on the development of therapies for neurocognitive and neurodegenerative disorders. Coronis owns a pipeline of several clinical- and preclinical-stage molecules and strives to build value through the clinical development of proprietary formulated drugs. The company's pipeline includes CP201, its leading drug, developed to treat ADNP syndrome. CP201 is a trans-nasally delivered peptide (NAP) developed for the treatment of ADNP syndrome in children. ADNP syndrome, an autism spectrum disorder, is a rare neurogenetic disease caused by de novo mutations in the ADNP gene. Coronis also develops CP101, a drug to treat cognitive impairment associated with schizophrenia (CIAS) using a proprietary new small peptide.
Identity
| Name | Coronis Neurosciences |
|---|---|
| Slug | coronis-neurosciences |
| Type / kind | startup |
| Crunchbase ID | coronis-neurosciences |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwJmpsdcIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, May 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Golda Meir 5, Ness Ziona, Israel |
Web & social
| https://www.linkedin.com/company/12902749 |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}